Wegovy 0.50 mg: the second step on the titration ladder

What 0.50 mg actually does that 0.25 mg doesn't

The 0.25 mg dose serves one purpose: giving your digestive system time to adjust to semaglutide without overwhelming it with nausea or vomiting. At that level, the pharmacological effect on appetite is modest. Moving to 0.50 mg is where most people first notice the medicine doing its job, appetite dips more noticeably, satiety after meals comes sooner, and the urge to snack between meals tends to quieten.

Semaglutide works by activating GLP-1 receptors involved in appetite signalling and slowing the rate at which the stomach empties. The dose-response relationship is real: higher doses produce greater receptor activation and, over time, greater average weight reduction. The full Wegovy dose schedule explains how each step builds on the last, but the short version is that 0.50 mg is a transition, not an endpoint. The STEP 1 trial's average weight loss of around 15% over 68 weeks was achieved at the 2.4 mg maintenance dose (published in the New England Journal of Medicine) not at earlier steps. If you want to understand how the different Wegovy mg strengths compare and what each is designed to achieve, that context makes it easier to see why expecting the same effect at 0.50 mg sets an unfair benchmark.

That said, some people do experience meaningful side effects at 0.50 mg. Nausea, loose stools, and reflux are the most common, typically peaking in the days after the injection and then settling during the week. If they have not eased before the next scheduled dose increase, a prescriber may hold you at 0.50 mg for an additional four weeks rather than moving straight to 1.0 mg. That is a clinical judgement, not a failure of the treatment.

How to make the decision about moving on

The titration schedule is a guide, not a countdown timer. The practical question at week eight or nine (when the 1.0 mg step is approaching) is whether your body has settled. A useful way to think about it: if you are still experiencing significant nausea most days, the 0.50 mg dose has not yet become your baseline. Moving up while your system is still unsettled usually means worse side effects at the higher dose, not faster results.

If side effects are manageable or have resolved, increasing as scheduled makes clinical sense. The evidence for meaningful weight reduction sits at higher doses, and staying at 0.50 mg indefinitely gives up most of the medicine's benefit. Wegovy 1 mg is where the therapeutic ladder begins in earnest for most people.

There is also the practical matter of the pen format. The 0.5 mg Wegovy pen delivers a pre-set 0.5 mg dose per injection; you do not adjust it yourself. Keep it refrigerated between 2°C and 8°C, and always check the Patient Information Leaflet for the exact room-temperature storage window before travelling, the SmPC figures vary and the leaflet is the authoritative source. Injecting on the same day each week helps maintain steady drug levels; many people find it easiest to pick a fixed point in the week, like a Sunday morning before the day gets busy.

Side effects at 0.50 mg and when to seek help

The side-effect profile at 0.50 mg mirrors the broader semaglutide picture: gastrointestinal effects lead the list. Nausea is the most reported, followed by constipation, diarrhoea, vomiting, and indigestion. These are documented thoroughly on the NHS semaglutide medicines page and are generally described as mild-to-moderate and transient.

Most side effects ease within the first week after a dose step and become less noticeable over time. Eating smaller portions, avoiding high-fat or very rich meals, and staying well hydrated all help. That last point matters more than people often expect, persistent vomiting or diarrhoea without adequate fluid intake can lead to dehydration, so if you cannot keep fluids down for an extended period, that warrants a call to a clinician.

Two situations require prompt medical attention rather than waiting it out. First, severe and persistent stomach pain that radiates toward the back (with or without vomiting) can be a sign of pancreatitis, which the MHRA flagged in a Drug Safety Update in January 2026 as a known, infrequent but serious risk with GLP-1 medicines; seek urgent help if this occurs. Second, signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing) need emergency care. You can report any suspected side effect using the MHRA's Yellow Card scheme.

If you are considering how the cost of Wegovy fits into your budget, that is a fair question, private treatment involves an ongoing commitment, and understanding what is included matters as much as the headline figure.

What a prescriber looks at before each dose step

A responsible prescriber does not simply rubber-stamp the next dose because four weeks have passed. At nume, every repeat order receives a fresh clinical review, a real prescriber reads your responses, not software. The kinds of things considered at the 0.50 mg review: whether side effects have been tolerable, whether weight is trending in the expected direction given where you are in the schedule, and whether anything in your health picture has changed since the last review.

People transferring from another provider at 0.50 mg are asked to provide evidence of their current dose and recent use. This protects you as much as anything else, jumping ahead without a verified clinical history increases the risk of unnecessary side effects. The about nume page explains how our pharmacy and prescribing team is structured, and our clinical team profile gives a clearer sense of who is reviewing your case.

If you have questions about eligibility or want to explore whether Wegovy is appropriate for your situation, checking your eligibility through a free consultation is the practical first step. The consultation is reviewed the same day it is submitted, a named prescriber, not software, reads your answers.